9115 Hague Road
Founded in 1896, Roche is a global pioneer in pharmaceuticals and diagnostics and is the world’s largest biotech company, focused on advancing science to improve people’s lives. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics. The Diagnostics division develops and produces medical tests that provide information to help healthcare professionals find the right treatment for patients and deliver the best patient care to improve, prolong and save lives.
We offer a wide range of research and in vitro (outside the body) diagnostic tools that help in the early detection, prevention, diagnosis and treatment of diseases like congestive heart failure, HIV, hepatitis and diabetes, as well as medical conditions like fertility and blood coagulation. These products and services are used by researchers, physicians, patients, healthcare facilities and laboratories around the world.
Roche Diagnostics has its North American headquarters in Indianapolis. The Roche campus, located at 96th Street and Hague Road, spans about 155 acres and is home to U.S. research and development, laboratory, manufacturing, distribution, IT and administrative operations. The campus supports six diagnostics business areas: Diabetes Care, Centralized Diagnostics, Sequencing and Life Science, Molecular Diagnostics, Point of Care Diagnostics and Tissue Diagnostics. About 4,000 employees report into Indianapolis, with about 2,900 working onsite.
Roche Molecular Solutions, one of the global business areas within Roche Diagnostics, brings together the diagnostic power of molecular, tissue and sequencing technologies.
With the goal of revolutionizing diagnostic decisions through integrated solutions, Roche Molecular Solutions brings together the latest technologies withinmolecular diagnostics (polymerase chain reaction or PCR-based testing), tissue diagnostics (tissue biopsy testing) and sequencing solutions (next-generation DNA and RNA sequence-based testing) to advance the standard of care for everyone.
4300 Hacienda Drive
Pleasanton, California 94588
1739 articles with Roche
Genentech Submits Supplemental New Drug Application to FDA for Venclexta Plus Gazyva for Previously Untreated Chronic Lymphocytic Leukemia with Co-Existing Medical Conditions
Genentech, a member of the Roche Group, announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration for Venclexta® in combination with Gazyva® in people with previously untreated chronic lymphocytic leukemia and co-existing medical conditions.
The study showed that artificial intelligence can be used to provide widespread, cost-effective eye screenings via telemedicine to assist ophthalmologists in improving vision outcomes.
Study of investigational personalized T-cell therapy IMA101 expanded to explore combination with anti-PDL1 antibody
Jeffrey D. Marrazzo, chief executive officer of Spark Therapeutics, said his company is the only biotech company that has successfully commercialized a gene therapy for a genetic disease in the United States.
Roche’s Flatiron Health and the U.S. Food and Drug Administration’s Information Exchange and Data Transformation (INFORMED) Program expanded a two-year-old collaboration agreement.
It’s nice to be admired. Fortune released its list of the most respected companies across the globe and one pharma company made the top 50 list.
For its 2019 list of the top 50 most innovative companies, Fast Company selected 10 from the biotech industry that are having a significant impact on the treatment of patients. The first five are highlighted.
Genentech announced that the U.S. Food and Drug Administration has accepted the company’s New Drug Applications and granted Priority Review for entrectinib
January was a rough month for many pharma employees in California, as several companies pulled the trigger on layoffs, or announced coming layoffs that will affect hundreds of employees.
There is a concept held dear by many that there is strength in diversity. At South San Francisco-based Genentech, that is a concept also embraced by Sara Kenkare-Mitra, senior vice president of development sciences.
As Britain’s plans to leave the European Union—Brexit—stagger toward the March 29 deadline, the UK biopharma industry is taking stock of the likely impact.
Alexander (Sasha) Opotowsky, associate professor at Harvard Medical School and a cardiologist at Boston Children’s Hospital and Brigham and Women’s Hospital took time out to speak with BioSpace about advances in heart health, congenital heart disease (CHD), biopharma, and the Adult Congenital Hea...
Chugai Pharmaceutical Co., Ltd. announced that Roche has joined the World Federation of Hemophilia Humanitarian Aid Program.
Genentech Submits Supplemental Biologics License Application to FDA for Kadcyla for Adjuvant Treatment of People With HER2-Positive Early Breast Cancer With Residual Disease After Neoadjuvant Treatment
Application is being reviewed under FDA's Real-Time Oncology Review and Assessment Aid pilot programs
According to WARN notices, the two companies will slash a total of 106 jobs starting in March.
Chugai Pharmaceutical Co., Ltd. announced that Roche has received notification that the EU Committee for Medicinal Products for Human Use adopted a positive opinion for Hemlibra®
Reports Preliminary Fourth Quarter and Full Year 2018 Revenue Results and Issues 2019 Financial Guidance
Roche announced that it was discontinuing two of its Alzheimer’s Phase III trials, CREAD I and 2, after a pre-planned interim analysis.
First Patient Enrolled in Pivotal Study of RG6042 (IONIS-HTT Rx) for People with Huntington's Disease
First of 4+ Ionis programs expected to advance to pivotal studies this year
As the United Kingdom nears closer and closer to exiting the European Union without a deal, drug manufacturers like Novartis are preparing contingencies for how they will continue to provide medications, many of them life-saving, for patients in the U.K.